Work headed by scientist Antonio Zorzano proposes a possible therapeutic target to treat fatty liver, a disease for which there is currently no treatment.
The study, which was done in collaboration with the Pere Virgili Institute, has been published in the journal Cell.
The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now.
The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies.
Mutations in L-amino acid transporters (LATs) can lead to a wide range of conditions, such as autism, hearing loss and aminoacidurias.
Published in the journal Nature Communications, this study presents key data on how amino acids bind to these transporters.
The work is a collaboration between IRB Barcelona, CIBERER, IBMB-CSIC and the Barcelona Supercomputing Center.
Many treatments against cancer, such as TRAIL, aim to trigger a type of cell death known as apoptosis.
A team at IRB Barcelona, headed by Antonio Zorzano, has demonstrated that the protein TP53INP2 induces apoptosis in chemotherapy treatments.
The breakthrough made by researchers at IRB Barcelona allows the study of the role of each molecular component in the stability and conformation of DNA crystals.
The new molecular simulation techniques are expected to reduce the time and cost of obtaining crystals in the laboratory.
The study, published in the journal Molecular Biology and Evolution, has been headed by Lluís Ribas, at IRB Barcelona.
Modesto Orozco’s lab has published a paper in Chemical Communications about a therapeutic tool to prevent treatment resistance in breast cancer.
The tool has been tested in tumour cells in vitro and will now need to be tested in animal models before moving on to the development of a valid treatment for patients.
A team headed by ICREA researchers Salvador Aznar Benitah and Fran Supek concludes that care should be taken with drugs that inhibit epigenetic factors.
Published in Nature Cell Biology, the study is a collaboration between a biomedical lab and a computational lab at IRB Barcelona.
Researchers at IRB Barcelona modify chlorotoxin—a small protein present in scorpion venom with blood-brain barrier permeability—to transport drugs into the brain.
The barrier, which protects the brain, prevents drugs used for the treatment of neurological diseases and brain tumours from entering the organ.
A study in mice done at IRB Barcelona and CNAG-CRG explains that dermal fibroblasts lose their cell identify over time and with it their capacity to produce and secrete collagen and other proteins.
